All your parcels are delivered in
DISCREET PACKAGING 100%
IMPORTANT: the use of the drug Eralfon 3000 IU is possible only after medical consultation with your doctor. The information provided on the NewPharmacy website is not a substitute for medical advice.
Information about the drug Eralfon 3000 IU: instructions, prices, analogues, generic and other related drugs.
Buy Eralfon 3000 IU from NewPharmacy online
Contents- Eralfon 3000 IU uses
- Eralfon 3000 IU dosage
- Eralfon synonyms and analogues
- Eralfon available forms
- Where to buy Eralfon 3000 IU online with delivery?
Eralfon 3000 IU uses
- anemia in patients with chronic renal failure, including those on hemodialysis;
- prevention and treatment of anemia in patients with solid tumors, anemia in which was the result of antitumor therapy;
- prevention and treatment of anemia in patients infected with the human immunodeficiency virus (HIV) caused by the use of zidovudine, with endogenous erythropoietin levels less than 500 IU / ml;
- prevention and treatment of anemia in patients with myeloma, low-grade non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis;
- treatment and prevention of anemia in premature infants born with low body weight (1.5 kg);
- within predeposit programs before extensive surgery in patients with a hematocrit level equal to 33-39%, to facilitate autologous blood collection and reduce the risk associated with the use of allogenic blood transfusions if the expected need for transfused blood exceeds the number which can be obtained by the method of autologous collection without the use of epoetin alpha;
- before performing an extensive operation with an expected blood loss of 900-1800 ml in adult patients without anemia or with mild to moderate anemia (hemoglobin level 100-130 g / l), to reduce the need for allogeneic blood transfusions and facilitate the recovery of erythropoiesis.
Eralfon 3000 IU dosage
Treatment of anemia in patients with chronic renal failure
Adults on hemodialysis. Eralphon is administered subcutaneously or intravenously at the end of a dialysis session. When changing the method of administration, the drug is administered in the same dose, then the dose is adjusted if necessary (with a subcutaneous method of administration of the drug, a dose of 20-30% less is required to achieve the same therapeutic effect than with intravenous administration). Treatment with the drug includes two stages.
1. Stage of correction: with subcutaneous administration of the drug, the initial single dose is 30 IU/kg 3 times a week. With intravenous administration of the drug, the initial single dose is 50 IU/kg 3 times a week. The correction period lasts until the optimal level of hemoglobin (100-120 g/l in adults and 95-110 g/l in children) and hematocrit (30-35%) is reached. These indicators should be monitored weekly.
The following situations are possible:
- hematocrit increases from 0.5 to 1% per week. In this case, the dose is not changed until the optimal parameters are reached;
- the rate of increase in hematocrit is less than 0.5% per week. In this case, it is necessary to increase the single dose by 1.5 times;
- growth rate of more than 1% per week. In this case, it is necessary to reduce the single dose of the drug by 1.5 times;
- the hematocrit remains low or decreases. It is necessary to analyze the causes of resistance before increasing the dose of the drug.
The effectiveness of therapy depends on the correct individual treatment regimen.
2. Stage of maintenance therapy: to maintain the hematocrit at the level of 30-35%, the dose of the drug used at the correction stage should be reduced by 1.5 times. Then the maintenance dose of the drug is selected individually, taking into account the dynamics of hematocrit and hemoglobin levels.
Children on hemodialysis. The initial dose is 50 U/kg 3 times a week. If necessary, a single dose is increased once every 4 weeks by 25 U/kg until the optimal concentration of hemoglobin is reached. Maintenance dose in children with a body weight of less than 10 kg-75-150 U/kg (average 100 U/kg) 3 times a week; 10-30 kg-60-150 U / kg (average 75 U/kg) 3 times a week; more than 30 kg — 30-100 U/kg (average 33 U/kg) 3 times a week.
Adult predialysis patients. The initial dose is administered subcutaneously or intravenously 3 times at 50 U / kg per week. If necessary, a single dose is increased 1 time in 4 weeks by 25 U/kg until the optimal concentration of hemoglobin is reached. The maintenance dose is 17-33 U/kg 3 times a week.
Prevention and treatment of anemia in patients with solid tumors
Before starting treatment, it is recommended to determine the level of endogenous erythropoietin. When the concentration of serum erythropoietin is less than 200 IU / ml, the initial dose of the drug is 150 IU/kg 3 times a week with an intravenous method of administration. If after 4 weeks of treatment the level of hemoglobin increases and is at least 10 g / l or the number of reticulocytes increased by more than 40,000 cells/ml above the initial level, the dose of the drug remains the same (150 IU/kg 3 times a week).
If after 4 weeks of treatment, the increase in hemoglobin level is less than 10 g / l and the increase in the number of reticulocytes is less than 40,000 cells/µl compared to the initial level, then during the next 4 weeks, the dose is increased to 300 IU/kg 3 times a week. If after an additional 4 weeks of treatment at a dose of 300 IU/kg, the hemoglobin level has increased and is at least 10 g / l or the number of reticulocytes increases by more than 40,000 cells/µl, then the existing dose of the drug is maintained (300 IU/kg 3 times a week). If after 4 weeks of treatment at a dose of 300 IU/kg, the hemoglobin level increased by less than 10 g/l and the increase in the number of reticulocytes is less than 40,000 cells/µl compared to the baseline level, treatment should be discontinued. If the hemoglobin level increases by more than 20 g / l during the month, the dose of the drug should be reduced by 25%. If the hemoglobin level exceeds 140 g / l, it is necessary to suspend treatment until the hemoglobin level drops below 120 g / l and then continue the administration of the drug at a dose 25% lower than the original one.
Therapy with the drug should continue for 1 month after the end of the course of chemotherapy.
The level of serum ferritin (or serum iron) should be determined in all patients before and during treatment with the drug. If necessary, an additional iron intake is prescribed.
Prevention and treatment of anemia in patients with HIV infection
It is recommended to determine the initial level of endogenous erythropoietin in the blood serum before starting treatment with Eralfon. The conducted studies show that at the level of erythropoietin more than 500 IU/ml, the effect of therapy with the drug is unlikely.
Treatment with the drug includes 2 stages.
1. Stage of correction: the drug is prescribed at a dose of 100 IU/kg 3 times a week subcutaneously or intravenously for 8 weeks. If after 8 weeks of therapy it was not possible to achieve a satisfactory effect (for example, to reduce the need for blood transfusions or to increase the level of hemoglobin), the dose can be gradually increased (no more than once every 4 weeks) by 50-100 IU/kg 3 times a week. If it was not possible to achieve a satisfactory effect of therapy with Eralfon at a dose of 300 IU / kg 3 times a week, then the appearance of a response to further therapy at higher doses is unlikely.
2. Stage of maintenance therapy: after achieving a satisfactory effect in the phase of correction of anemia, the maintenance dose should provide a hematocrit level in the range of 30-35%, depending on the change in the dose of zidovudine, the presence of concomitant infectious or inflammatory diseases. If the hematocrit is more than 40%, the administration of the drug should be discontinued until the hematocrit decreases to 36%. When resuming therapy, the dose of epoetin alpha should be reduced by 25%, followed by adjustment to maintain the required level of hematocrit. The level of serum ferritin (or serum iron) should be determined in all patients before and during treatment with the drug. If necessary, an additional iron intake is prescribed.
Prevention and treatment of anemia in patients with myeloma, low-grade non-Hodgkin's lymphoma, and chronic lymphocytic leukemia
In these patients, the expediency of treatment with epoetin alfa is due to the inadequate synthesis of endogenous erythropoietin against the background of anemia. When the level of hemoglobin is below 100 g / l and serum erythropoietin is below 100 IU / ml, Eralfon is administered subcutaneously at a starting dose of 100 IU/kg 3 times a week. Laboratory monitoring of hemodynamic parameters is carried out weekly. If necessary, the dose of the drug is adjusted in the direction of increasing or decreasing every 3-4 weeks. If an increase in the level of hemoglobin is not observed when the weekly dose of 600 IU/kg is reached, further use of epoetin alpha should be discontinued as ineffective.
Prevention and treatment of anemia in patients with rheumatoid arthritis
In patients with rheumatoid arthritis, there is a suppression of the synthesis of endogenous erythropoietin under the influence of an increased concentration of proinflammatory cytokines. Treatment of anemia in these patients is carried out with a drug with subcutaneous administration at a dose of 50-75 IU / kg 3 times a week. If the hemoglobin level increases by less than 10 g / l after 4 weeks of treatment, the dose of the drug is increased to 150-200 IU/kg 3 times a week. A further increase in the dose seems impractical.
Treatment and prevention of anemia in premature infants born with low body weight
Eralfon is administered subcutaneously at a dose of 200 IU / kg 3 times a week, starting from the 6th day of life until the target values of hemoglobin and hematocrit levels are reached, but no more than 6 weeks.
Adult patients participating in the autologous blood collection program before surgery
It is recommended to use the intravenous route of administration of the drug. Epoetin alpha should be administered at the end of the blood collection procedure.
Before prescribing the drug, all contraindications to the collection of autologous blood should be taken into account. Before surgery, Eralfon should be prescribed 2 times a week for 3 weeks. At each visit to the doctor, a portion of blood is taken from the patient (if the hematocrit is ≥33% and / or the hemoglobin level is ≥110 g / l) and stored for autologous transfusion. The recommended dose of Eralfon is 600 IU / kg/2 times a week.
The level of serum ferritin (or serum iron) should be determined in all patients before and during treatment with the drug. If necessary, an additional iron intake is prescribed.
In the presence of anemia, its cause should be established before starting therapy with epoetin alfa. It is necessary to ensure an adequate intake of iron in the body as soon as possible by prescribing an oral iron preparation at a dose of 200 mg/day (based on divalent iron), and maintain iron intake at this level throughout the course of therapy.
Patients in the pre-and postoperative period who do not participate in the autologous blood collection program
It is recommended to use subcutaneous administration of the drug at a dose of 600 IU / kg per week for 3 weeks preceding the operation (21, 14 and 7 days before the operation), and on the day of the operation. If necessary, when for medical reasons it is necessary to shorten the preoperative period, Eralfon can be prescribed daily at a dose of 300 IU / kg for 10 days before the operation, on the day of the operation and for 4 days after the operation. If the level of hemoglobin in the preoperative period reaches 150 g / l or higher, the use of epoetin alpha should be discontinued. Before starting therapy with epoetin alfa, it is necessary to make sure that patients do not have iron deficiency.
All patients should receive an adequate amount of iron (oral 200 mg / day based on bivalent iron) throughout the course of treatment. If possible, additional oral iron intake should be provided before starting therapy with epoetin alfa to ensure adequate iron storage in the patient's body.
Eralfon synonyms and analogues
International name: Epoetin alpha, Epoetin, Erythropoietin, EPO, Haematopoietin, Haemopoietin, Eritropoietina, Eritropoyetina, Hemopoyetina.
Pharmacological Group: Erythropoiesis stimulators
Analogues and related drugs of the medicine Eralfon:
- Eprex 2000 IU 6 syringes
- Eprex 4000 IU 6 syringes
- Eprex 10000 IU 6 syringes
- Eprex 40000 IU 1 syringe
- Myrcera 100 mcg
- Myrcera 150 mcg
- Myrcera 75 mcg
- Myrcera 50 mcg
- Aranesp 20 mcg
- Aranesp 300 mcg
- Aranesp 30 mcg
- Aranesp 500 mcg
- Recormon 2000 IU 6 syringes
- Recormon 10000 IU 6 syringes
- Recormon 30000 IU 1 syringe
- Vero Epoetin 2000 iu 1 bottle
- Erythropoietin 2000 IU 10 ampoules
- Binocrit 2000 IU 6 syringes
- Binocrit 3000 IU 6 syringes
- Binocrit 5000 IU 6 syringes
- Binocrit 10000 IU 6 syringes
- Binocrit 30000 IU 1 syringe
- Binocrit 40000 IU 6 syringes
- Epocrin 1000 IU 10 ampoules
- Epocrin 2000 IU 10 ampoules
- Epocrin 4000 IU 10 ampoules
- Epocrin 10000 IU 10 ampoules
- Epostin 2000 IU 1 syringe
- Epostin 2000 IU 10 ampoules
- Epostin 10000 IU 10 ampoules
Eralfon available forms
Release form: Solution for injection 3000 IU 0.3 ml 6 syringes
Manufacturer: Sotex, Rusia
You also can buy Eralfon with other dosage and form:
- Eralfon 2000 IU 6 syringes
- Eralfon 2500 IU 6 syringes
- Eralfon 5000 IU 6 syringes
- Eralfon 10000 IU 1 syringe
- Eralfon 40000 IU 1 syringe
Where to buy Eralfon 3000 IU online with delivery?
NewPharmacy offers Eralfon 3000 IU for sale with Worldwide Mail Shipping. All medicines are shipped from Russia. We ship to all over the world except the country of Germany.
We ship any medicines only after full payment is made. Eralfon 3000 IU cost is indicated for 1 pack (unit).
Our online pharmacy sells only original, 100% authentic medicines (drugs).
Our pharmacy does not have accounts in such services as Amazon, Ebay, Reddit or others.
